Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 17;12(4):e35.
doi: 10.5415/apallergy.2022.12.e35. eCollection 2022 Oct.

Anaphylaxis is rare due to CoronaVac in a population of healthcare workers

Betül Özdel Öztürk  1 , İrem Akdemir  2 , Alpay Azap  2 , Gülfem Çelik  1 , Sevim Bavbek  1 , Dilşad Mungan  1
Affiliations

Anaphylaxis is rare due to CoronaVac in a population of healthcare workers

Betül Özdel Öztürk et al. Asia Pac Allergy. .

Abstract

Background: CoronaVac, the first coronavirus disease 2019 vaccine administered in our country, was found safe in clinical trials.

Objective: We aimed to reveal the rate and features of CoronaVac vaccine-associated allergic reactions among vaccinated healthcare workers (HCWs) in real-life.

Methods: This study was planned as a questionnaire-based study. Participants who reported a postvaccination allergic reaction were interviewed on phone and their medical records were also checked for confirmation.

Results: A total of 2,488 HCWs took part in the study and 4,054 postvaccination complete questionnaire-responses were obtained. Twenty-one HCWs (female: male, 17:4) with a mean age of 40.95 ± 10.09 stated that they had an allergic reaction after a total of 23 vaccine injections. Accordingly, the reaction rate was 0.56% among all vaccine doses. The most common reactions were systemic skin reactions (2.7%) consisting of generalized pruritus, diffuse pruritic erythema, urticaria, and maculopapular rash. That was followed by local injection site reaction (0.12%). Anaphylaxis was reported in 4 cases (0.09%) with a mean onset time of 12 ± 6 minutes. One of them had a history of anaphylaxis with 2 drugs, another had venom and food allergy. Three of the subjects had level 2 diagnostic certainty according to the Brighton Collaboration criteria and one had level 3. All anaphylaxis cases were discharged within 24 hours and none of them required intensive care.

Conclusion: Our study demonstrated that allergic reactions to CoronaVac were rare and mostly mild. Although anaphylaxis was also rare, the importance of early intervention with close follow-up was once again emphasized.

Keywords: Anaphylaxis; COVID-19; CoronaVac; Local injection site reaction; Systemic skin reactions; Vaccine-associated allergic reactions.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no financial conflicts of interest.

Figures

Fig. 1
Fig. 1. Types of reported allergic reactions.
See this image and copyright information in PMC

References

    1. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–527. - PubMed
    1. Gupta R, Sharma V, Sridhara S, Singh BP, Arora N. Identification of serine protease as a major allergen of Curvularia lunata. Allergy. 2004;59:421–427. - PubMed
    1. Sinovac Research and Development Co. Ltd. Safety and immunogenicity study of inactivated vaccine for prophylaxis of SARS CoV-2 infection (COVID-19) Bethesda (MD): ClinicalTrials.gov; 2022. [cited 2022 Feb 22]. Available from: https://clinicaltrials.gov/ct2/show/NCT04352608 .
    1. Republic of Turkey Ministry of Health. COVID-19 Vaccination Information Platform. Turkish National COVID-19 vaccine administration strategy [Internet] Ankara (Turkey): Republic of Turkey Ministry of Health; 2022. [cited 2022 Feb 22]. Available from: https://covid19asi.saglik.gov.tr/EN-78317/turkish-national-covid-19-vacc... .
    1. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–192. - PMC - PubMed